Clinical Trial

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-03-10; most recent amendment 2026-05-26.
Status change: Active, Not Recruiting → Recruiting 2026-05-26
Status change: Recruiting → Active, Not Recruiting 2024-12-10
Status change: Not Yet Recruiting → Recruiting 2022-03-24
Trial Details
NCT Number NCT05289167
Lead Sponsor Northwell Health
Conditions Graft-versus-host Disease
Enrollment 74 participants
Start Date 2022-03-13
Primary Completion 2026-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-29